GHK: A Naturally Occurring Tripeptide of Tissue Repair and Genomic Modulation

Research summary. GHK (Gly-His-Lys) is a tripeptide that occurs naturally in human plasma, saliva, and urine. It was first isolated and characterised by Pickart and colleagues in the 1970s. Plasma GHK levels decline substantially with age — from approximately 200 ng/mL at age 20 to roughly 80 ng/mL at age 60 in published surveys — a decline that has supported decades of interest in the molecule as a marker and modulator of tissue repair capacity. The peptide is biologically released by proteolytic processing of collagen and the SPARC protein following tissue injury, where it appears to function as a regenerative signalling molecule.

Molecular profile

• Sequence: Gly-His-Lys (GHK)
• Molecular formula: C₁₄H₂₄N₆O₄ (free peptide)
• Molecular weight: ~340.4 g/mol (free peptide); copper-bound form is the more bioactive species in many contexts (covered separately as GHK-Cu)
• Origin: Naturally occurring; cleaved from collagen and SPARC during ECM remodelling

The relationship between free GHK and its copper-bound form (GHK-Cu) is important: the copper complex is thought to be the dominant active species in many in-vivo settings, since GHK has high affinity for Cu(II) and copper plays a central role in several of GHK's reported activities. The "GHK Basic" page in this catalogue refers to the unmodified tripeptide; the copper complex is treated separately.

Mechanism of action

GHK has been studied across an unusually broad range of biological readouts, with effects largely converging on transcriptional reprogramming of tissue-repair- and senescence-associated gene sets. Reported mechanisms include:

• Activation of DNA repair gene expression. Microarray studies of GHK-treated cells have reported upregulation of approximately 47 genes involved in DNA repair pathways and downregulation of approximately 5 — a pattern consistent with restoration of genomic maintenance capacity.
• Activation of the ubiquitin-proteasome system (UPS). GHK has been associated with broad upregulation of UPS-related genes (~41 upregulated, 1 downregulated in published profiles), supporting clearance of damaged proteins.
• Suppression of fibrinogen and IL-6 expression. GHK reduces transcription of the FGB (fibrinogen β-chain) gene and dampens IL-6 production, with downstream consequences for the acute-phase response.
• Modulation of the insulin/IGF-1 pathway. GHK has been reported to suppress several genes in the insulin/IGF-1-like signalling pathway, a pathway with established connections to organismal aging in evolutionarily conserved models.
• Antioxidant gene activation. Upregulation of approximately 14 antioxidant-system genes alongside suppression of pro-oxidant genes has been described.
• Modulation of TGF-β superfamily signalling. GHK has been linked to changes in TGF-β signalling associated with tissue repair and ECM remodelling.

Preclinical research highlights

Wound healing. Cell-culture and rodent studies have reported that GHK exposure increases collagen, glycosaminoglycan, and proteoglycan synthesis in dermal preparations, and accelerates closure of dermal wounds in animal models — particularly when combined with copper as GHK-Cu.

Cancer-cell expression profiling. Genomic studies in metastatic colon cancer cell lines have reported that GHK exposure normalises expression of a set of genes associated with metastatic phenotype, with reversal of expression patterns characteristic of aggressive disease toward a more quiescent profile. These observations are model-system findings and have not been advanced to clinical investigation.

Hair follicle and dermal applications. Topical GHK formulations have been examined in hair-growth and skin-rejuvenation contexts, with reported effects on follicle-cycle markers, dermal fibroblast activity, and skin barrier protein expression.

Cognition and CNS. In rodent models, GHK has been reported to modulate inflammation in CNS tissue and to influence markers of neuronal survival, with some literature attributing these effects to copper-dependent activities.

Pulmonary studies. Mouse models of bleomycin-induced pulmonary fibrosis have reported attenuated fibrotic remodelling with GHK administration, attributed to reductions in TNF-α and IL-6 expression in lung tissue.

Genomic-scale activity

One of the more striking features of the GHK literature is the breadth of transcriptional changes reported in response to a tripeptide. The published profile suggests modulation of expression of several thousand genes, of which the patterns most consistently reported are those described above — DNA repair, UPS, antioxidant, fibrinogen, IL-6, and TGF-β-related pathways. The mechanism by which a tripeptide produces transcriptional effects of this scope is not fully resolved; copper-dependent activities, transcription-factor modulation, and direct chromatin effects have all been proposed.

Current research status

GHK remains a research peptide widely used in dermatologic, regenerative, and aging-biology studies. It is included in many cosmetic formulations as a labelled ingredient (often as the copper complex), where regulatory framing differs from that of a therapeutic. As a therapeutic, GHK is not an approved drug, and clinical translation has been slow despite the breadth of preclinical interest.

Key takeaways for researchers

• GHK is a naturally occurring tripeptide (Gly-His-Lys) released during ECM remodelling and present at declining concentrations with age in human plasma.
• Its biology in many contexts is mediated by the copper-bound form, GHK-Cu, treated separately.
• Reported mechanisms span DNA repair, ubiquitin-proteasome system activation, antioxidant gene expression, and modulation of fibrinogen and inflammatory cytokines.
• It is widely used in cosmetic products and is the subject of ongoing research in tissue repair, dermatology, and aging biology.
• It is not an approved therapeutic.

References

1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987.

---

This article is provided for educational and research purposes only. GHK is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.